Curis continues to make significant strides in its clinical studies, particularly with emavusertib for hard-to-treat lymphomas, while reducing its net losses year-over-year.

• Curis reported a narrower net loss of $7.7 million for Q3 2025, down from $10.1 million in Q3 2024, reflecting improved operational efficiency.
• Research and development expenses decreased to $6.4 million in Q3 2025, driven by lower clinical and manufacturing costs.
• The company is poised to support accelerated submission for its emavusertib study in both the U.S. and Europe following strong interest from regulatory bodies.
• Initial results from the AML triplet study show promising disease response rates, with MRD conversion seen in 50% of evaluable patients.
• Curis' cash position remains stable at $9.1 million, expected to fund operations into 2026 amidst ongoing clinical trials.